Spruce Biosciences, Inc.
SPRB
Rank in Stocks
#18184
Spruce Biosciences, Inc., founded in 2014 and situated in Daly City,... Spruce Biosciences, Inc., founded in 2014 and situated in Daly City, California, operates as a biopharmaceutical enterprise. Its primary objective is to advance and bring to market innovative treatments, particularly for uncommon endocrine conditions. A central component of its therapeutic pipeline is tildacerfont, a non-steroidal drug candidate. This compound is currently undergoing Phase 2b clinical assessments in adult patients with congenital adrenal hyperplasia (CAH), with the aim of optimizing disease management and lessening dependence on steroid medications by examining reductions in glucocorticoid levels and their clinical consequences. Tildacerfont is also progressing through Phase 2 trials for pediatric classic CAH, as well as investigating its efficacy in women suffering from polycystic ovary syndrome (PCOS). Additionally, Spruce Biosciences maintains a collaborative licensing agreement with Eli Lilly and Company to jointly explore, formulate, and commercialize various pharmaceutical substances.
Share Price
$49.34
Last synced: 2026-11-09
Market Cap
$141.80M
Change (1 day)
5.99%
Change (1 year)
-56.20%
Country
Stock data: Financial Modeling PrepΒ·Updated Β·Not investment adviceΒ·How we calculate this
Trade Spruce Biosciences, Inc. (SPRB)
Category
Healthcare
Operating Margin for Spruce Biosciences, Inc. (SPRB)
Operating Margin as of November 2026 TTM: 0.00%
According to Spruce Biosciences, Inc.'s latest financial reports, its current operating margin (TTM) is 0.00%. At the end of 2025 the company had an operating margin of 0.00%.
Operating Margin history for Spruce Biosciences, Inc. from 2018 to 2026
Operating Margin at the end of each year
| Year | Operating Margin | Change |
|---|---|---|
| 2026 (TTM) | 0.00% | 0.00% |
| 2025 | 0.00% | -100.00% |
| 2024 | -1,143.37% | 121.87% |
| 2023 | -515.34% | 0.00% |
| 2022 | 0.00% | 0.00% |
| 2021 | 0.00% | 0.00% |
| 2020 | 0.00% | 0.00% |
| 2019 | 0.00% | 0.00% |
| 2018 | 0.00% | 0.00% |
Operating Margin for similar companies or competitors
| Company | Operating Margin | Operating Margin Difference | Country |
|---|---|---|---|
| 38.59% | - |
US
|
|
| -149.01% | - |
US
|
|
| 25.57% | - |
AU
|
|
| 31.23% | - |
BE
|
|
| 29.35% | - |
NL
|
What is a company's Operating Margin?
The operating margin is a key indicator to assess the profitability of a company. Higher operating margins are generaly better as they show that a company is able to sell its products or services for much more than their production costs. The operating margin is calculated by dividing a company's earnings by its revenue.
Questions about Spruce Biosciences, Inc.'s operating margin
What was Spruce Biosciences, Inc.'s operating margin in 2025?
In 2025, Spruce Biosciences, Inc.'s operating margin was 0.00%, compared with -1,143.37% in 2024.
How has Spruce Biosciences, Inc.'s operating margin changed since 2020?
From 2020 to 2025, Spruce Biosciences, Inc.'s operating margin was highest in 2025 (0.00%) and lowest in 2024 (-1,143.37%).
How does Spruce Biosciences, Inc.'s operating margin compare with similar companies?
Spruce Biosciences, Inc.'s operating margin (0.00%) is higher than that of 1 of the 5 similar companies listed above. The highest among them is Vertex Pharmaceuticals Incorporated, with 38.59%.